Schering-Plough Cutback Target: $1.5 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Head count first to lower, as results from cholesterol trial take their toll.
You may also be interested in...
As Sales Slip, Merck & Co. Plans 7,200 Job Cuts
Facing lower sales of Vytorin, Singulair and Gardasil, on top of recent pipeline disappointments, Merck implements a new restructuring initiative.
As Sales Slip, Merck & Co. Plans 7,200 Job Cuts
Facing lower sales of Vytorin, Singulair and Gardasil, on top of recent pipeline disappointments, Merck implements a new restructuring initiative.
Schering-Plough Backs Out Of Asentar Agreement With Novacea
"Unexpected" decision comes after failed Phase III trial in prostate cancer.